If you are looking for high risk, high reward investment options, then read on.
That's because the speculative ASX stock in this article could rise approximately 80% over the next 12 months according to analysts at Bell Potter.
Here's what it is recommending to clients with a high tolerance for risk.
Image source: Getty Images
Which speculative ASX stock?
The stock that is being recommended is EMvision Medical Devices Ltd (ASX: EMV).
It is a medical device company that is aiming to change the stroke care model.
The speculative ASX stock's lead product in development is a portable, cost-effective, non-ionising and safe brain scanner called Emu. It will be capable of rapidly determining the presence of suspected stroke and stroke type to provide game-changing insights for clinicians.
Its second product and likely main revenue generator according to Bell Potter is First Responder. It is a pre-hospital based device the size of a motorcycle helmet that can be used by standard road or air ambulances where fast access to CT/MRI scanning is limited.
Bell Potter notes that the company is progressing through its preparatory phase. It said:
EMV has moved through its preparatory phase and fully activated recruiting for the trial, following completion of onboarding, training verification and site activation processes. A second site at Mt Sinai has been activated and a second site at Memorial Hermann will soon activate to accelerate recruitment.
The network of KOL sites across the trial group should prove valuable in building commercial foundations for the emu product. The Continuous Innovation Study is designed to support algorithm and feature development, while the Regional Benefits Study (RBS) is moving toward an ethics submission with planned activation in 2H CY26. The RBS is designed to support broader adoption of the emu.
The broker also highlights that the speculative ASX stock is running studies for First Responder, with preliminary findings due next month. It adds:
EMV is continuing to move through the Mobile Stroke Unit Study, the Aeromedical Retrieval Study and the Standard Road Ambulance Clinical Study. These studies examine workflow, integration, and usability in a variety of settings, which is necessary for building the 510(k)-application process and commercial prospects. Next month, EMV will be presenting preliminary findings of the Aeromedical study at the International Stroke Conference, giving the First Responder critical exposure to over 6,000 clinicians, researchers, and stroke professionals.
Big potential returns
According to the note, Bell Potter has retained its speculative buy rating and $3.15 price target on the ASX stock.
Based on its current share price of $1.76, this implies potential upside of approximately 80% for investors over the next 12 months.
Bell Potter's bullish view is based on its belief that 2026 will be a pivotal year for the company. It said:
CY26 is a pivotal year for EMV with an expected successful completion of the current validation trial, leading to potential FDA De Novo clearance in 4Q CY26 / 1Q CY27, as well as the completion of the various First Responder feasibility studies. Both these developments should present valuation inflection points for EMV.
